삼성서울병원

Ko En

Ahn, Myung Ju M.D

TITLE
Professor, Department of Hematology & Oncology, Samsung Medical Center
Treament Schedule 06 月
DATE
TUE
01
WEB
02
THU
03
FRI
04
SAT
05
SUN
06
MON
07
TUE
08
WEB
09
THU
10
FRI
11
SAT
12
SUN
13
MON
14
TUE
15
WEB
16
THU
17
FRI
18
SAT
19
SUN
20
MON
21
TUE
22
WEB
23
THU
24
FRI
25
SAT
26
SUN
27
MON
28
TUE
29
WEB
30
AM
PM
Treament Schedule 07 月
DATE
THU
01
FRI
02
SAT
03
SUN
04
MON
05
TUE
06
WEB
07
THU
08
FRI
09
SAT
10
SUN
11
MON
12
TUE
13
WEB
14
THU
15
FRI
16
SAT
17
SUN
18
MON
19
TUE
20
WEB
21
THU
22
FRI
23
SAT
24
SUN
25
MON
26
TUE
27
WEB
28
THU
29
FRI
30
SAT
31
AM
PM

Medical School

Hanyang University College of Medicine

Specialty Training

Fellowship   Asan Medical Center
Residency   Hanyang University Hospital
Internship   Hanyang University Hospital

Other Education

Master: Hanyang University Graduate School
Ph.D: Hanyang University Graduate School
Postdoctoral fellowship: Memorial Sloan Kettering Cancer Center, USA

Clinical & Research Interests

Medical Oncology (Lung cancer, Head and neck cancer, Esophageal cancer)

Participation in Academic Societies
and Research

Member, Korean Medical Association
Member, Korean Association of Internal Medicine
Member, Korean Association of Oncology
Member, Korean Association for Cancer Research
Member, American Society of Oncology
Member, International Association Society of Lung Cancer
Member, European Society of Medical Oncology
Member, Korean Association of Clinical Oncology
Member, Korean Association Society of Lung Cancer
Member, Korean Head and Neck Cancer Society

Selected Publications

  • IMMUNE NETW 2020 10.4110/in.2020.20.e48 Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs Kim1, KH; Hur, JY; Koh, J; Cho, J; Ku, BM; Koh, JY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Shin, EC
    View PubMed
  • EUR J CARDIO-THORAC 2020 10.1093/ejcts/ezaa181 Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation Lee1, J; Choi, JY; Lim, SW; Ahn, MJ; Park, K; Zo, JI; Shim, YM; Oh, D; Sun, JM
    View PubMed
  • ANN ONCOL 2020 10.1016/j.annonc.2020.08.2234 Osimertinib in central nervous system progressive EGFR-mutant lung cancer do we need to detect T790M? Park1, S; Ahn, MJ
    View PubMed
  • ANN ONCOL 2020 10.1016/j.annonc.2020.08.2100 Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor AURA3 overall survival analysis Papadimitrakopoulou1, VA; Mok, TS; Han, JY; Ahn, MJ; Delmonte, A; Ramalingam, SS; Kim, SW; Shepherd, FA; Laskin, J; He, Y; Akamatsu, H; Theelen, WSME; Su, WC; John, T; Sebastian, M; Mann, H; Miranda, M; Laus, G; Rukazenkov, Y; Wu, YL
    View PubMed
  • J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.018 Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status Lee1, J; Choi, YL; Han, J; Park, S; Jung, HA; Su, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed